Slomovitz on Tisotumab Vedotin's Promise for Cervical Cancer | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Slomovitz on Tisotumab Vedotin's Promise for Cervical Cancer | Targ…
1 month ago
targetedonc.com
Disitamab Vedotin: Promising HER2-Targeted Therapy for Urothelial Cancer - Matthew Galsky
Disitamab Vedotin: Promising HER2-Targeted Therapy for Uroth…
6 months ago
urotoday.com
Dr Goldman on the Efficacy of Telisotuzumab Vedotin in Advanced NSCLC With c-MET Overexpression | OncLive
Dr Goldman on the Efficacy of Telisotuzumab Vedotin in Advanc…
10 months ago
onclive.com
FDA Approval of Tisotumab Vedotin for Recurrent or Metastatic Cervical Cancer | OncLive
FDA Approval of Tisotumab Vedotin for Recurrent or Metastatic Cervic…
Nov 1, 2021
onclive.com
Disitamab Vedotin: Promising HER2-Targeted Therapy for Urothelial Cancer - Matthew Galsky
Disitamab Vedotin: Promising HER2-Targeted Therapy for Uroth…
Sep 15, 2024
urotoday.com
A combination of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine has been shown to improve progression-free survival in Hodgkin's lymphoma. Data on overall survival are needed. New research findings are summarized in a short video. https://nej.md/3BciZAQ | The New England Journal of Medicine
2:15
A combination of brentuximab vedotin plus doxorubicin, vinblast…
3.7K viewsJul 27, 2022
FacebookThe New England Journal of Medicine
EV-302/KEYNOTE-A39: Open-Label, Randomized Phase 3 Study of Enfortumab Vedotin in Combination with Pembrolizumab vs Chemotherapy in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma | OncLive
14:04
EV-302/KEYNOTE-A39: Open-Label, Randomized Phase 3 Study of Enf…
Oct 31, 2023
onclive.com
8:43
Clinical Trials Evaluating Tisotumab Vedotin in Patients with Recurren…
Jan 10, 2024
onclive.com
ASCO® 2024 Insights: "Impact of Exposure on Outcomes With Enfo…
198 viewsJun 6, 2024
vumedi.com
13:30
innovaTV 301/ENGOT-cx12/GOG-3057: A Global, Randomized, Ope…
Oct 31, 2023
onclive.com
Erdafitinib versus enfortumab vedotin in previously treated uroth…
Apr 6, 2021
urologytimes.com
2:13
Quick Take: Tisotumab Vedotin for Recurrent Cervical Cancer
878 viewsJul 9, 2024
FacebookThe New England Journal of Medicine
2:51
Adcetris (Brentuximab Vedotin) – What You Need to Know: Uses, Do…
199 viewsAug 24, 2024
YouTubeAstroByte
Dr Bedke on the Safety Profile of Enfortumab Vedotin/Pembrolizum…
7 months ago
onclive.com
3:11
Pharmacology of Brentuximab Vedotin (Adcetris); Pharmacokinet…
113 viewsMar 24, 2025
YouTubeMBBS NAIJA
Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid C…
Oct 12, 2021
nejm.org
3:38
Brentuximab Vedotin Overview and Treatment Advice
2.8K viewsJan 28, 2019
YouTubeOncLive
1:18
The role of enfortumab vedotin in urothelial cancer treatment
366 viewsMay 31, 2024
YouTubeVJOncology
6:36
Enfortumab Vedotin (Padcev) for bladder cancer
393 viewsAug 14, 2024
YouTubePharmComm
3:58
Optimizing Brentuximab Vedotin Use in Hodgkin Lymphoma
138 viewsOct 29, 2018
YouTubeTargeted Oncology
4:59
iMeta | Efficacy vedotin combined immunotherapy in patients with m…
23 views11 months ago
YouTubeiMeta Science
POLIVY® (polatuzumab vedotin-piiq) Mechanism of Action
Aug 14, 2023
polivy-hcp.com
ECHELON-1 Trial: Brentuximab Vedotin With Chemotherapy Offer…
Aug 8, 2022
ascopost.com
18:13
Brentuximab Unveiling the Role of Anti-CD30 in Cancer Research
118 viewsMar 7, 2025
YouTubeAssay Genie
1:58
Enfortumab vedotin for the treatment of advanced urothelial c…
196 viewsDec 11, 2023
YouTubeVJOncology
0:54
Polatuzumab Vedotin: A New Hope in Blood Cancer Treatment
230 views7 months ago
YouTubeDr. Rajib Bhattacharjee
4:36
Polatuzumab Vedotin: A New Hope in Blood Cancer Treatment
49 views7 months ago
YouTubeDr. Rajib Bhattacharjee
15:05
Enfortumab Vedotin in Relapsed/Refractory Bladder Canc…
19 views7 months ago
YouTubeCancer Research and Statistic Foundation
1:16
Brentuximab vedotin (Adcetris) mode of action
645 viewsJan 27, 2023
YouTubeAsif Biotech
2:12
Up to 40% of patients receiving the standard R-CHOP regimen for diff…
5.6K viewsJan 27, 2022
FacebookThe New England Journal of Medicine
See more videos
Static thumbnail place holder